Clinical Trial Update: Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial NCT07079475 is testing DZD6008 in combination with Sunvozertinib for advanced EGFR-mutant non-small cell lung cancer and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DZD6008
• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING